IRVING, Texas – May 4, 2026
Caris Life Sciences has secured MolDX approval for its flagship Caris ChromoSeq™ assay, marking a major advancement in genomic diagnostics technology for myeloid malignancies and significantly improving clinical access, reimbursement eligibility, and real-world adoption. The approval, granted under the Molecular Diagnostic Services (MolDX) Program, validates the test’s clinical utility, analytical performance, and medical necessity, positioning ChromoSeq as a next-generation MedTech solution in oncology diagnostics. This milestone is particularly critical for diseases such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN), where accurate, rapid, and comprehensive genomic profiling directly influences treatment decisions and patient outcomes, making this approval both a technological and commercial inflection point for Caris.
Ultra-Deep Sequencing Technology Redefines Diagnostics
At the center of this development is Caris ChromoSeq, described as the world’s first ultra-deep whole genome sequencing (WGS) assay specifically engineered for myeloid cancers, delivering sequencing depth up to eight times higher than conventional WGS, which dramatically improves the sensitivity and accuracy of detecting complex genomic alterations; this includes single nucleotide variants (SNVs), insertions and deletions (indels), copy number alterations, structural variants, and gene fusions, all captured within a single integrated platform, eliminating the need for multiple fragmented diagnostic tests that traditionally slow down oncology workflows; by consolidating all genomic insights into a single, easy-to-interpret clinical report, ChromoSeq enhances diagnostic efficiency, reduces turnaround time, and minimizes errors, positioning it as a high-value MedTech innovation in precision oncology where speed and completeness are critical.
MolDX Approval Unlocks Market Access and Adoption
The MolDX approval is a key reimbursement and market access milestone, as it enables coverage consideration under Medicare systems, significantly increasing the likelihood of widespread adoption across hospitals, cancer centers, and diagnostic laboratories in the United States; importantly, this approval confirms that ChromoSeq meets strict benchmarks for clinical validity and actionable utility, which are essential for payer confidence, physician trust, and large-scale deployment, while also reinforcing Caris’ strategy to replace outdated multi-test workflows with a single comprehensive genomic solution, thereby reducing cost inefficiencies, redundant testing, and delays in care delivery, which remain major challenges in oncology diagnostics; from a business standpoint, this positions ChromoSeq as a scalable, revenue-generating MedTech platform rather than just a niche diagnostic tool.
Advertisement
Driving the Future of AI-Powered Precision Medicine
With this milestone, Caris Life Sciences strengthens its leadership in AI-driven precision medicine and advanced diagnostic technologies, leveraging its large-scale clinico-genomic database, machine learning models, and high-performance computing infrastructure to decode the molecular complexity of cancer, while ChromoSeq plays a crucial role by generating high-resolution genomic datasets that support diagnosis, risk stratification, therapy selection, and disease monitoring; this aligns with the company’s broader vision of integrating whole genome, whole exome, and transcriptome sequencing into a unified platform, ultimately enabling data-driven, personalized treatment strategies, and signaling a wider industry shift toward comprehensive, technology-driven diagnostics replacing traditional single-marker testing approaches, which are increasingly seen as insufficient for managing complex cancers.
Source: Caris Life Sciences press release
